Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2026

Summary of Significant Accounting Policies

Schedule of the items included within net loss regularly provided to the CODM

	Three months ended March 31,
	2026		2025
Revenue	$	19,059	$	18,520
Cost of revenue (excluding amortization of intangible assets)		6,444		5,913
Amortization of intangible assets		95		95
Gross profit		12,520		12,512
Sales and marketing:
Sales and sales management		10,796		11,614
International		1,959		1,357
Other sales and marketing (a)		3,782		3,637
Total sales and marketing		16,537		16,608
General and Administrative:
Finance and Legal		2,027		1,951
Other general and administrative (b)		2,139		1,885
Total general and administrative		4,166		3,836
Research and Development:
Clinical		1,059		939
Regulatory and quality		540		440
Other research and development (c)		744		1,161
Total research and development		2,343		2,540
Other segment items (d)		(1,747)		(792)
Net loss	$	(12,273)	$	(11,264)
(a) Other sales and marketing includes strategy, analytics and allocated facility expenses.
(b) Other general and administrative includes executive, human resources, information technology and allocated facility expenses.
(c) Other research and development includes engineering and allocated facility expenses.
(d) Other segment items include other operating income and other expenses as disclosed in the consolidated statements of operations and comprehensive loss; interest expense, loss on extinguishment of debt, other income and income tax expense.

Schedule of reconciliation of all captions of cash, cash equivalents and restricted cash

	March 31,
	2026		2025
Cash and cash equivalents	$	39,541	$	42,833
Restricted cash		250		265
Total cash and cash equivalents and restricted cash shown in statements of cash flows	$	39,791	$	43,098

Schedule of Disaggregation of Revenue

The following table presents revenue disaggregated by the Company’s portfolio of products (in thousands):

	Three months ended March 31,
	2026		2025
OviTex	$	12,619	$	12,109
OviTex PRS		5,881		6,044
Other		559		367
Total revenue	$	19,059	$	18,520

Schedule of fair value of assets and liabilities measured on recurring basis

The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):

	Fair value measurement at reporting date using
	Quoted prices in
	active markets		Significant other		Significant
	for identical		observable		unobservable
	assets		inputs		inputs
	(Level 1)		(Level 2)		(Level 3)
March 31, 2026:
Cash equivalents – money market fund	$	36,970	$	—	$	—
December 31, 2025:
Cash equivalents – money market fund	$	47,068	$	—	$	—

Schedule of dilutive securities excluded

	Three months ended March 31,
	2026	2025
Stock options	3,543,623	2,535,298
Unvested restricted stock units	2,024,383	1,211,483
Common stock warrants	88,556	88,556
Common stock warrants issued with credit agreement	2,000,000	—
Total	7,656,562	3,835,337